Preventing Organ Transplant Rejection: Immunosuppressive Regimens and Monitoring

Transplant rejection occurs when the recipient's immune system recognizes donor HLA antigens as foreign. Lifelong immunosuppression is the cornerstone of prevention, balanced against infection and malignancy risks.

Induction Therapy (Peri-transplant, High-Intensity)

  • IL-2 Receptor Antagonists (Basiliximab): Blocks IL-2R on activated T-cells; low side-effect profile; used in low-immunologic-risk kidney/pancreas transplants.
  • Depleting Antibodies (Thymoglobulin/ATG, Alemtuzumab): Lymphocyte depletion; reserved for high-risk recipients (retransplant, high PRA, ABO-incompatible).

Maintenance Immunosuppression (Triple Therapy Standard)

ClassAgentsMechanismKey Monitoring
Calcineurin Inhibitors (CNI)Tacrolimus (Tac), Cyclosporine (CsA)Block IL-2 transcription → T-cell activationTrough levels, renal function, glucose, BP, neurotoxicity
AntiproliferativesMycophenolate (MMF/MPA), AzathioprineInhibit purine synthesis → lymphocyte proliferationCBC (leukopenia, anemia), GI, LFTs
CorticosteroidsPrednisoneBroad anti-inflammatory, genomic effectsGlucose, bone density, cataracts, weight, infection

Newer/Adjunct Agents

  • mTOR inhibitors (Sirolimus, Everolimus): CNI-sparing, anti-neoplastic; risks include wound healing impairment, hyperlipidemia, proteinuria.
  • Belatacept (CTLA4-Ig): Costimulation blocker; IV monthly; better renal function but higher early acute rejection; contraindicated in EBV-negative patients.
  • JAK inhibitors (Tofacitinib): Emerging for refractory rejection.

Rejection Types & Treatment

  • Acute Cellular Rejection (ACR): T-cell mediated; biopsy-proven; treat with pulse steroids ± thymoglobulin.
  • Antibody-Mediated Rejection (AMR): Donor-specific antibodies (DSA) + C4d + histology; treat with plasmapheresis, IVIG, rituximab, bortezomib, eculizumab.
  • Chronic Rejection: Fibrosis, vasculopathy; limited reversibility; optimize maintenance, consider retransplant.

Monitoring & Long-Term Care

  • Protocol biopsies (kidney) or surveillance (heart: gene expression, echo; lung: bronchoscopy).
  • DSA monitoring (single antigen beads).
  • Cancer screening (skin, PTLD, cervical), cardiovascular risk reduction, bone health, vaccination (inactivated pre-transplant; live contraindicated).

Individualized regimens, therapeutic drug monitoring, and multidisciplinary care optimize graft survival.

Kidney Disease - Related Articles